Welcome to our dedicated page for Enliven Therapeutics news (Ticker: ELVN), a resource for investors and traders seeking the latest updates and insights on Enliven Therapeutics stock.
News and updates for Enliven Therapeutics, Inc. (Nasdaq: ELVN) focus on its progress as a clinical-stage biopharmaceutical company developing small molecule precision oncology therapies. Enliven regularly issues press releases on clinical data, corporate developments, financings and governance changes that shape its trajectory in chronic myeloid leukemia (CML) and related oncology indications.
A central theme in Enliven’s news flow is the development of ELVN-001, its selective BCR::ABL kinase inhibitor for CML. Company announcements have highlighted Phase 1 and Phase 1b data from the ENABLE trial, including major molecular response rates, deep molecular responses, and safety and tolerability findings in heavily pretreated patients. Additional news covers data presentations at major medical meetings such as EHA, SOHO, ESH-iCMLf, DGHO, JSH and ASH, including subsets like patients with atypical fusion transcripts.
Investors and observers will also find financial results and capital markets updates, including quarterly earnings press releases with selected condensed consolidated financial information and disclosures on public offerings of common stock and pre-funded warrants. These items provide context on Enliven’s cash position and its ability to fund clinical development.
Governance and leadership developments are another recurring news category. Recent releases have described the appointment of a new Chief Executive Officer, changes in board composition, and inducement equity grants under the company’s 2025 Inducement Equity Incentive Plan. For anyone tracking ELVN, this news page offers a centralized view of clinical milestones, regulatory and scientific visibility, financing activities and leadership updates related to Enliven’s precision oncology programs.
Enliven Therapeutics (Nasdaq: ELVN) reported significant progress in Q2 2025, highlighted by positive Phase 1 clinical trial results for ELVN-001 in chronic myeloid leukemia (CML) treatment. The trial demonstrated a 47% cumulative MMR rate, with 32% of patients achieving MMR by 24 weeks, surpassing historical data from competitor treatments.
The company strengthened its financial position through a $230 million public offering, ending Q2 with $490.5 million in cash and equivalents, extending runway into H1 2029. Quarterly financials showed R&D expenses of $21.5 million and a net loss of $25.3 million. Enliven plans to initiate a Phase 3 pivotal trial in 2026.
Enliven Therapeutics (NASDAQ: ELVN), a clinical-stage biopharmaceutical company specializing in small molecule therapeutics, has announced its participation in three major upcoming investor conferences in May and June 2025:
- TD Cowen's 6th Annual Oncology Innovation Summit on May 27, 2025, at 1:00 p.m. ET
- Jefferies Global Healthcare Conference on June 4, 2025, at 4:20 p.m. ET
- Goldman Sachs Annual Global Healthcare Conference on June 10, 2025, at 4:00 p.m. ET
All presentations will be in fireside chat format and will be webcast live through the company's investor relations website, with recordings available for 90 days after each event.
The trial showed a 44% cumulative major molecular response (MMR) rate (16 of 36 patients) by 24 weeks, with 26% achieving and 100% maintaining MMR. The study enrolled 74 heavily pretreated patients, with 66% having received three or more prior tyrosine kinase inhibitors (TKIs).
ELVN-001, a selective BCR::ABL1 kinase inhibitor, demonstrated strong efficacy in resistant cases, with 40% of TKI-resistant patients achieving MMR. The drug showed a favorable safety profile across all doses, with low rates of dose interruptions (<10%) and reductions (<5%). The results will be presented at the EHA 2025 Congress in Milan.
Enliven Therapeutics (Nasdaq: ELVN) has announced it will present five posters at the 2025 AACR Annual Meeting in Chicago from April 25-30, 2025. The presentations will showcase their pipeline of small molecule therapeutics, including:
- ELVN-002: A selective HER2 inhibitor with potential enhanced efficacy in combination with antibody-drug conjugates
- ELVN-001: A selective ABL1 tyrosine kinase inhibitor for chronic myeloid leukemia treatment
- ELV-3111: A type 1 pan-RAF inhibitor for NRAS and BRAF mutant cancers
The presentations will cover pharmacokinetics, drug resistance mechanisms, and combination therapy approaches. All posters will be presented on April 29, 2025, across different sessions and locations at the conference.
Enliven Therapeutics (ELVN) has reported its Q4 and full year 2024 financial results, highlighting continued progress in its clinical programs. The company maintains a strong financial position with $313.4 million in cash and equivalents, providing runway into mid-2027.
Key pipeline updates include anticipated Phase 1 data for ELVN-001, their BCR::ABL kinase inhibitor for chronic myeloid leukemia (CML), expected mid-2025. Their second program, ELVN-002, a CNS-penetrant HER2 inhibitor, will report both monotherapy and combination trial data in H2 2025.
Financial highlights for FY2024 show R&D expenses of $80.8 million (up from $64.6M in 2023), G&A expenses of $23.8 million (up from $19.0M), and a net loss of $89.0 million (compared to $71.6M in 2023). The company is preparing for a potential pivotal trial of ELVN-001 in 2026.